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Available online 11 January 2010Loss of Omi/HtrA2 function leads to nerve cell loss in mouse models and has been linked to
neurodegeneration in Parkinson's and Huntington's disease. Omi/HtrA2 is a serine protease
released as a pro-apoptotic factor from the mitochondrial intermembrane space into the cytosol.
Under physiological conditions, Omi/HtrA2 is thought to be involved in protection against cellular
stress, but the cytological and molecular mechanisms are not clear. Omi/HtrA2 deficiency caused
an accumulation of reactive oxygen species and reduced mitochondrial membrane potential. In
Omi/HtrA2 knockout mouse embryonic fibroblasts, as well as in Omi/HtrA2 silenced human HeLa
cells and Drosophila S2R+ cells, we found elongated mitochondria by live cell imaging. Electron
microscopy confirmed the mitochondrial morphology alterations and showed abnormal cristae
structure. Examining the levels of proteins involved in mitochondrial fusion, we found a selective
up-regulation of more soluble OPA1 protein. Complementation of knockout cells with wild-type
Omi/HtrA2 but not with the protease mutant [S306A]Omi/HtrA2 reversed the mitochondrial
elongation phenotype and OPA1 alterations. Finally, co-immunoprecipitation showed direct
interaction of Omi/HtrA2 with endogenous OPA1. Thus, we show for the first time a direct effect of
loss of Omi/HtrA2 on mitochondrial morphology and demonstrate a novel role of this
mitochondrial serine protease in the modulation of OPA1. Our results underscore a critical role
of impaired mitochondrial dynamics in neurodegenerative disorders.
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Omi/HtrA2 (high temperature requirement protein A2) is a
nuclear encoded serine protease that localizes to the mitochon-
drial intermembrane space, and is released into the cytosol
upon apoptosis [1]. The pro-apoptotic function of the Omi/
HtrA2 protease is at least partially mediated by binding and
proteolytic removal of inhibitor of apoptosis proteins [2-4].
However, recent in vivo and in vitro data indicate that Omi/
HtrA2 has physiological cytoprotective role(s) within the
mitochondria of non-apoptotic cells. In fact, loss of Omi/HtrA2
may contribute to selective neurodegeneration [5,6]. Loss of
mitochondrial serine protease activity in mnd2 mice, which is
caused by a homozygous point mutation in the Omi/HtrA2
gene, leads to a phenotype with muscular wasting and striatal
neurodegeneration [7,8]. Likewise, targeted disruption of the
Omi/HtrA2 gene in mice led to progressive, severe striatal
neuron loss, consequently resulting in a locomotor phenotype
[6]. Interestingly, in striatal neurons of mutant huntingtin
overexpressing mice as well as in the affected brain regions of
human Huntington's disease patients, reduced levels of Omi/
HtrA2 were found [5], supporting the notion that Omi/HtrA2
deficiencies are involved in neurodegeneration. Finally, muta-
tions in the Omi/HtrA2 gene have been implicated as a
susceptibility factor in German and Belgian patients with
sporadic Parkinson's disease (PD) [9,10].
Recent studies in various neurodegenerative diseases have
shown that altered mitochondrial function and dynamics take
center stage in neuronal viability [11], particularly in PD [12].
Mitochondria are metabolically active and highly dynamic
organelles that constantly undergo fusion and fission events in
order to maintain integrity. This has not only implications for
mitochondrial morphology, but the control of these antagonistic
activities is directly linked to mitochondrial function [13,14]. Due
to the specific energy needs of the nervous system and the non-
dividing character of the implicated cell type, disturbed
mitochondrial dynamics are critical for the accumulation of
dysfunctional mitochondria characterized by increased produc-
tion of reactive oxygen species (ROS), decreased mitochondrial
membrane potential and damaged mitochondrial DNA. In this
context, proteins that directly modulate mitochondrial fusion
have been found mutated in neurodegenerative diseases like
Charcot-Marie-Tooth 2A (Mitofusin-2 (Mfn2); [15]) or autoso-
mal-dominant optic nerve atrophy (optic atrophy protein 1
(OPA1); [16,17]). Mutations in the OPA1 protein as well as
increased proteolytic processing of OPA1 lead to impaired
mitochondrial fusion and dysfunction of the organelle [18,19].
Recently, also other PD associated genes, namely Parkin and
PINK1, have been directly linked to mitochondrial homeostasis
[20] and morphology [21].
Based on the critical involvement of mitochondrial function
in neurodegeneration and aging processes and due to the role of
mutations in the Omi/HtrA2 gene as possible susceptibility
factors in PD [9,10], we studied the consequences of loss of Omi/
HtrA2 protein in fibroblasts from knockout mice [6] as well as in
silenced human HeLa and Drosophila melanogaster S2R+ cells.
We describe for the first time a role of Omi/HtrA2 in the
regulation of the key fusion protein OPA1 that is linked to
mitochondrial elongation.Materials and methods
Cell lines and culture
Immortalized mouse embryonic fibroblasts (MEFs) from Omi/
HtrA2 knockout (KO) mice and wild-type (WT) controls [6] were
grown in Dulbecco's modified Eagle's medium (Invitrogen) with
added 10% fetal calf serum (Perbio Science) and 1% penicillin/
streptomycin (Invitrogen). Both cell lines were kept at the same
passage number for experimental consistency.
Stably transfected human embryonic kidney HEK293 cells were
generated using pCMV-Tag4 empty vector (Stratagene) or con-
taining humanWT Omi/HtrA2-FLAG insert [9]. HEK293 cells were
transfected using Fugene6 (Roche), and positive clones selected by
the continued addition of 500 μg/ml G-418 (Invitrogen) to the
growth medium.
A human cell line derived from cervical cancer (HeLa) was used
for silencing experiments. HeLa cells were cultured in Dulbecco's
modified Eagle's medium (Invitrogen) with added 10% fetal calf
serum (Perbio Science). All cells were incubated in a 5% CO2
humidified atmosphere at 37 °C.
Drosophila S2R+ cells were cultured in Schneider's medium
(Invitrogen) supplemented with 5% fetal calf serum (Sigma) and
1% penicillin/streptomycin (Invitrogen-Gibco).
Stably re-transfected KO MEF cells were generated using
human WT or a protease dead mutant (S306A) of Omi/HtrA2
without the FLAG tag (see above) subcloned into the pcDNA 3.1/
Zeo vector (Invitrogen) or empty vector as control. The S306A
mutant was cloned using the Stratagene QuikChange II Site-
DirectedMutagenesis Kit according tomanufacturer's instructions.
Omi/HtrA2 KO MEF cells were transfected using Fugene6 (Roche),
and positive clones selected by the continued addition of 500 μg/
ml zeocin (Invivogen) to the growth medium.
Flow cytometry
For all flowcytometrymeasurements, the cellswereharvested using
phosphate-buffered saline (PBS) with 2mMEDTA andwashed once
with PBS after which they were stained with appropriate dyes.
To measure levels of cellular reactive oxygen species (ROS), the
cells were stained with 10 μM 2′,7′-dichlorohydrofluorescein
diacetate (Invitrogen) in PBS for 30 min at 37 °C. The cells were
thenwashed twicewith PBS, resuspended in PBS and kept on ice for
the measuring procedure. For each sample, ∼20,000 cells were
measured using the 488 argon laser and emission through the FITC
filter (530 nm) of a CyAn flow cytometer (DakoCytomation).
To measure the levels of mitochondrial superoxide, the cells
were stained with 5 μM MitoSOX Red (Invitrogen) in PBS for
15 min at 37 °C. The cells were then washed once with PBS and
resuspended in PBS. For each sample, ∼70,000 cells were
measured using the 488 argon laser and emission through the PE
filter (575 nm).
To measure the mitochondrial membrane potential, the cells
were stained with 100 nmMitoTracker Green FM andMitoTracker
CM-H2XRos (Invitrogen) in PBS for 15 min at 37 °C. The cells were
then washed once with PBS and resuspended in PBS. For each
sample, ∼70,000 cells were measured using the 488 argon laser
and emission through the PE Texas Red filter (613 nm) and the
FITC filter (530 nm).
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compared against WTMEF cells and re-transfected vector controls
were compared againstWTOmi/HtrA2 re-transfected KO cells. For
measurements of mitochondrial ROS, the threshold was set at
about 50% of the WT signal intensity and the percentage of shift in
the fluorescence activated cell sorter (FACS) staining was
determined with the Summit version 4.2 software (DakoCytoma-
tion). All the presented results are the means of three independent
experiments performed in duplicate and are presented as relative
change compared to the WT condition.
Analysis of mitochondrial morphology
MEF and HeLa cells were stained 10 min at 37 °C with 125 nM
MitoTracker Green FM and Hoechst 33342 in DMEM medium (all
Invitrogen). The cells were then washed once with PBS and
covered with DMEM. For each cell line, pictures were taken from
live cells using a Cell Observer (Carl Zeiss) at 37 °C and 5% CO2.
Each cell was classified into one of the following groups related to
the predominant phenotype of mitochondria: elongated, middle
sized or fragmented using the same criteria for each picture. For
HeLa cells, two categories were applicable for scoring: elongated
and normal. A number of 100–150 cells were scored per
experiment and each experiment was done at least in triplicate.
The scoring was done by an unbiased investigator blinded to the
genotype and the treatment of the cells.
For Drosophila mitochondrial morphology analysis, live cells
were incubated with 200 μM rhodamine 123 and imaged directly
in growing medium. Quantification of mitochondria length was
performed using the ImageJ software as previously described [22].
RNA interference
Silencing of Omi/HtrA2 was performed with HiPerformance siRNA
(Qiagen), targeting the following sequence of human Omi/HtrA2,
5′-CAGCACCTGCCGTGGTCTATA-3′. A scrambled siRNAwas used as
control (Qiagen). HeLa cells were transfected with 5 nM siRNA on
three consecutive days using HiPerFect (Qiagen) according to
manufacturer's instruction. Cells were transferred into chamber-
slides for immunofluorescence after the third transfection and
analyzed 2 days later. Protein expression and silencing were
verified by Western blot analysis.
Double stranded RNAs were prepared using MEGA script kit
(Ambion). Primers used to generate dsRNAs are available upon
request. S2R+ cells were plated (1.2×106 per well) in a 6-well
plate and treated with 15 μg dsRNA in serum-free medium using
Effectene (Qiagen). Two hours after dsRNA treatment, complete
medium was added to the wells and cells were cultured for 2 days
before being imaged.
Electron microscopy
Omi/HtrA2 KO and WT MEFs were fixed in 2.5% glutaraldehyde in
Hank's modified salt solution (HMSS), postfixed in 1% OsO4 in
0.1 M cacodylate buffer, scraped off, centrifuged and dehydrated in
a series of ethanol. The 70% ethanol step was saturated with uranyl
acetate for contrast enhancement. Dehydration was completed in
propylene oxide and the specimens were embedded in Araldite
(Serva). Ultrathin sections were produced on a FCR Reichert
Ultracut ultramicrotome (Leica), mounted on pioloform-coatedcopper grids and contrasted with lead citrate. Specimens were
analyzed and documented with an EM 10A electron microscope
(Zeiss). Subsequently mitochondria were counted and categorized
in 50 cells of each condition.
Western blot analysis
Cells were harvested with 2 mM EDTA in PBS and lysed with TNE
(50 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA and 10 mM
NaPP) containing 1% Triton X-100 (Sigma) and Complete protease
inhibitor cocktail (Roche). Protein concentration was measured
using Bradford solution (Bio-Rad) in a microplate reader and the
protein lysate (20-35 μg) was separated by SDS-PAGE. Alterna-
tively, 150,000 cells were counted, harvested and lysed directly in
Laemmli SDS-PAGE sample buffer (62.5 mM Tris–HCl [pH 6.8], 2%
sodium dodecyl sulfate (SDS), 5% β-mercaptoethanol, 10% glycer-
ol, 0.01% bromophenol blue) by boiling, before subjecting them to
SDS-PAGE. Western blots were analyzed by antibodies against
Omi/HtrA2, mitochondrial fission 1 protein (Fis1) (both from
Axxora), OPA1 (BD Transduction Laboratories), mitofusin 2
(Mfn2) or β-actin (both from Sigma), adenine nucleotide
transporter (ANT) or voltage dependent anion channel 1
(VDAC1) (both from Calbiochem), prohibitin (NeoMarkers), and
heat shock protein 90 (Hsp90; Stressgen).
S2R+ cells were harvested in RIPA buffer (50 mM Tris–HCl
[pH 7.4], 150 mM NaCl,), supplemented with Complete
protease inhibitor cocktail. Protein concentration was measured
using Bradford solution (Sigma) and the protein lysate (20–
30 μg) was separated by SDS-PAGE, after addition of loading
buffer (50 mM Tris–HCl; pH 6.8, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol, 12.5 mM EDTA, 0.02% Bromophenol Blue ).
Western blots were analyzed using antibodies against Omi/
HtrA2 (1:1000, kindly provided by M. Martins) and anti-β-
tubulin (1:10000, Sigma). For detection, secondary antibodies
conjugated with HRP (Chemicon) were used (1:5000), and
immunoreactivity was visualized with ECL chemiluminescence
(Amersham).
For densitometric analyses of OPA1 levels onWestern blots, the
ImageJ software (Rasband, W.S., ImageJ, U.S. National Institutes of
Health, USA, http://rsb.info.nih.gov/ij/, 1997–2007) was used. For
Fig. 5B, OPA1 levels were normalized to the loading control and
further all samples were compared to Omi/HtrA2 WT MEF levels
which were set to 100%. The results represent the mean of
comparison of three independent experiments. For the fold change
calculation in Fig. 7D, the densitometric analysis of the indicated
band was performed for each treatment and these were compared
to the untreated controls (0 min of both WT and KO).
Immunoprecipitation
For immunoprecipitation in HEK293 cells stably overexpressing
Omi/HtrA2, lysates were made with an immunoprecipitation lysis
buffer (50 mM HEPES [pH 7.5], 10 mM KCl, 50 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 1.5 mMMgCl2, 10% glycerol, 0.2% NP-40) and
were incubated with anti-FLAG agarose beads (Sigma) overnight
at 4 °C. After 5 washes with lysis buffer the samples were analyzed
by Western Blot analysis.
For immunoprecipitation from mouse brain, one hemisphere
from a C57/Bl6 mouse was homogenized in homogenization
buffer (50 mM Tris [pH 7.5], 1% [v/v] NP-40, 2 mM EDTA, 100 mM
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(Fluka) was added and the mixture incubated on ice for 30 min. To
remove cell debris, the lysates were centrifuged twice after which
Protein G agarose alone or pre-incubated with OPA1 antibody was
added and incubated overnight at 4 °C before it was washed and
analyzed by Western blotting.
RT-PCR
Total mRNA was isolated from MEF cells using peqGOLD TriFast
reagent followingmanufacturer's instructions (Peqlab) and 600 ng
total RNA was reverse transcribed using Transcriptor High Fidelity
cDNA Synthesis Kit (Roche) and anchored oligo-dT Primer to
exclude non-message RNA from reverse transcription. Two
microliters of RT reaction was subsequently used as template for
transcript amplification in a 25 μl reaction with 5 μl 5× GoTaq
Buffer, 0.1 μl GoTaq Polymerase (Promega) and 2 μM specific
primers for OPA1 designed to amplify all isoforms (sense 5′-
ACTCAGTTTATGTTCACCAC-3′, antisense 5′-AGAGCACACAATATT-
CAAAC-3′) and for β-actin (sense 5′-GGGTCAGAAGGACTCCTACG-
3′, antisense 5′-GGTCTCAAACATGATCTGGG-3′). The annealing
temperature was 48 °C for OPA1 and 52 °C for β-actin amplifica-
tion, respectively. Elongation time was 30 s in both cases. Cycle
number was chosen in the linear range of amplification of each
transcript (27 cycles for OPA1 and 20 cycles for β-actin), according
to the expression level. Amplified PCR products were resolved by
1% agarose gel electrophoresis and stained with an ethidium
bromide solution (Carl Roth).
For mRNA quantification in Drosophila cells, total RNA was
extracted using TRI Reagent (Sigma) or RNeasy Mini Kit (Qiagen)
following manufacturer's instruction. Total RNA (1.5 μg) was
reverse-transcribed by using a random decamer primer (RETRO-
script kit, Ambion). Quantitative real-time PCR was performed
using the SYBR Green Master Mix method (Sigma) with a Bio-Rad
MyiQ system. Primers used are as follows: for Omi/HtrA2 (sense
5′-GCCCTGGCGGATAATAGTAA-3′ and antisense 5′-GCTGCATA-
CAGGTTAAACTAGGG-3′) and for the housekeeping gene GAPDH
(sense 5′-GCGAACTGAAACTGAACGAG-3′ and antisense 5′-
CCAAATCCGTTAATTCCGAT-3′).
Mitochondrial isolation and proteinase K digest
Omi/HtrA2 WT and KO cells were grown to 100% confluence on
two 15 cm plates, harvested, washed twice with PBS and
resuspended in mitochondrial isolation buffer (MIB) (250 mM
sucrose, 20 mM HEPES [pH 7.5], 3 mM EDTA and Complete
protease inhibitor cocktail). The cells were disrupted by 25
passes with a glass douncer and subsequently 15 passes through
a 20 Gauge needle before they were centrifuged at 830×g for
10 min. From this, the supernatant was retained and the pellet
resuspended in MIB and disrupted as before, and again
centrifuged at 830×g for 10 min. The combined supernatants
were further centrifuged at 16,800×g for 10 min. The superna-
tant was kept as the cytosolic fraction and the pellet washed
twice more with MIB before resuspended in 100 μl MIB. The
protein concentration was measured using Bradford solution.
The purity of the preparation was confirmed by immunoblot
analysis. For proteinase K digest, 20 μg mitochondria were
subjected to 20 ng proteinase K (Merck, EC 3.4.21.64) digestion
at 37 °C for 0, 5, 10, 20, and 40 min. The reaction was stoppedwith 0.8 μl stop solution (100 mM EDTA, 40 mM phenylmethyl-
sulphonyl fluoride) before the mitochondria were spun down at
16,000×g for 10 min and resuspended in PAGE sample buffer for
immunoblot analysis.
Statistical analysis
Experimental results for mitochondrial morphology were ana-
lyzed for statistical significance using the Student's t-test
implemented in Microsoft Excel Software. For analysis of the
mitochondrial length in Drosophila S2R+ cells, the significance
was determined by ANOVA with a Bonferroni post hoc
correction. For statistical significance of the densitometrically
analyzed Western blot experiments, a one-way ANOVA and a
Student Newman–Keuls post hoc correction were performed
using GraphPad InStat version 3.00 for Windows 95 (GraphPad
Software, San Diego California USA, www.graphpad.com).Results
Increased ROS in Omi/HtrA2 KO MEF Cells
First we analyzed the effects of Omi/HtrA2 KO on mitochondrial
function and integrity. Dysfunction of mitochondria is typically
reflected by disturbed oxidative phosphorylation and leads to
the generation of ROS. Intramitochondrial ROS production was
quantified using MitoSOX Red, a fluorogenic dye that is targeted
to the mitochondria and readily oxidized by superoxide, but not
by other ROS- or reactive nitrogen species-generating systems
[23]. We found a significant increase in intramitochondrial ROS
in MEF cells from Omi/HtrA2 KO mice compared to WT controls
(Fig. 1A). Moreover, total ROS levels, measured by 2′,7′-
dichlorohydrofluorescein diacetate conversion, were elevated.
An average 15.2%±1.2% increase was observed in the Omi/
HtrA2 KO MEFs (p=0.0022) (data not shown). These results
demonstrate substantial oxidative stress occurring in MEF cells
devoid of Omi/HtrA2, confirming previously published findings
that show increased ROS production in immortalized Omi/HtrA2
KO MEF cells [24]. This could be related to decreased respiration,
as shown previously for brain mitochondria isolated from Omi/
HtrA2 KO mice [24].
Decreased mitochondrial membrane potential in Omi/HtrA2
KO MEF cells
We next examined the effects of Omi/HtrA2 knockout on the
mitochondrial membrane potential (MMP). We measured the
MMP by flow cytometry of cells dual-labeled with MitoTracker
Green FM and MitoTracker CM-H2XRos (Invitrogen). As Mito-
Tracker Green FM labels all mitochondria independently of
membrane potential and MitoTracker CM-H2XRos is only taken
up into mitochondria with an intact membrane potential, a ratio
between these two signals allows to determine how many of the
cells counted have mitochondria with an intact membrane
potential. As this method simultaneously compares mitochondria
with an intact membrane potential to all mitochondria, it controls
for the loss of mitochondrial mass as a potential source for
decreased signal. Omi/HtrA2 KO MEF showed a significant
decrease in MitoTracker Red/Green signal compared to WT
Fig. 1 – Analysis of ROS levels and mitochondrial membrane
potential in Omi/HtrA2WT andKOMEF cells. (A)Mitochondrial
ROS levels were analyzed by staining with the fluorescent dye
MitoSOX. (⁎p<0.006). (B, C) MMP was determined by a double
staining with MitoTracker GreenFM and MitoTracker
CM-H2XRos. (B) The ratio of MitoTracker GreenFM to
Mitotracker CM-H2XRos stainingwasmeasured as a readout for
the MMP (⁎p< 0.003). Error bars show the standard deviation
(SD). (C) Scattergraph representative of an Omi/HtrA2 WT
(left graph) and KO (right graph) MEF MMPmeasurement. The
selected area in blue represents the measured cells with intact
MMP. The loss of signal in the marked area indicates a decrease
inMMP. All results are given as relative comparisons toWT. The
results represent the mean of three independent experiments.
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These results were confirmed using tetramethylrhodaminemethyl
ester as a single dye technique (data not shown), the latter being in
line with previous studies [25,26]. The consistent MMP reduction
in Omi/HtrA2 KO MEF cells clearly demonstrates that Omi/HtrA2
is necessary for the maintenance of an intact MMP.
Mitochondrial morphology regulated by Omi/HtrA2
Recent data underscore the relevance of mitochondrial dynamics
in neurodegeneration. It has been shown that mitochondrial
dysfunction leading to free radical generation and loss of energysupply is involved in dynamic morphological alterations of
mitochondria [11]. To monitor mitochondrial morphology, we
performed fluorescence microscopy based on MitoTracker green
and concomitant Hoechst 33342 nuclear staining. This was
performed using live cell imaging in order to avoid fixation
artifacts. In Omi/HtrA2 KO cells, we found an increased proportion
of cells that display sustained, elongated, net-like structure of
mitochondria (Figs. 2A–C).
Mitochondrial ultrastructure was analyzed by electron mi-
croscopy. Control MEF cells displayed typical round shaped
mitochondria with well-formed cristae (Figs. 2D–F). In contrast,
Omi/HtrA2 KO cells exhibited a substantial amount of mito-
chondria with altered morphology (Figs. 2G–I). Semiquantitative
analysis revealed that 44.5% of the mitochondria in Omi/HtrA2
KO MEF cells show these alterations while only 8.6% mitochon-
dria in Omi/HtrA2 WT MEFs have abnormal mitochondrial
ultrastructure. Typical alterations were bulged, extended mito-
chondria, often with less inner membrane structures and no
observable cristae structure, including a loss of cristae junctions.
At many sites, in particular if the mitochondria were cut
longitudinally, we observed a local loss of cristae, whereas the
other end of the mitochondrium was still normal. If the part
with the lost cristae was cross sectioned, the mitochondrium
seemed to be completely devoid of folded inner membrane
structures. These alterations of mitochondrial ultrastructure are
consistent with the elongated morphology seen with light
microscopy (Fig. 2).
To control for cell type and species specific effects, we
extended our morphological studies to human HeLa cells and
Drosophila S2R+ cells. Transient silencing of Omi/HtrA2 in HeLa
cells using an siRNA approach resulted in a clear loss of the
protein (Fig. 3A) and morphologically a similar phenotype as in
MEF cells devoid of Omi/HtrA2, namely elongated mitochondria
(Figs. 3B–D). Similarly, the transient silencing of Omi/HtrA2 in
Drosophila S2R+ cells lead to a loss of both Omi/HtrA2 mRNA
(Fig. 3E) and protein (Fig. 3F) and an elongation of the
mitochondria as measured by the length of the mitochondria
(Figs. 3G–I). As a comparison, known fission and fusion genes
were also silenced (Fig. 3I). The effect of Omi/HtrA2 silencing on
mitochondrial morphology was comparable to the effects of
silencing the established fission proteins Fis1 and dynamin-
related protein 1 (Drp1) in Drosophila. These results clearly
underscore a well conserved role of Omi/HtrA2 in regulating
mitochondrial morphology.
Mitochondrial morphology relies on Omi/HtrA2 protease
function
To investigate whether the altered mitochondrial phenotype
seen upon loss of Omi/HtrA2 can be reversed and whether it is
dependent on the protease function of the protein, we stably
transfected KO MEF cells with empty vector or a plasmid
expressing human WT Omi/HtrA2 cDNA. In addition, we
generated a protease dead mutant [S306A]Omi/HtrA2 [2-4]
and produced the corresponding stably re-transfected MEF cell
lines. Indeed, re-transfection of WT Omi/HtrA2 (Fig. 4A), but not
an empty vector (Fig. 4B), was able to revert the mitochondrial
phenotype in Omi/HtrA2 KO MEFs to a similar degree as
observed in MEFs from wild-type littermate controls (Fig. 2C).
In contrast, the protease dead mutant was not able to normalize
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cation of mitochondrial morphology demonstrated the statistical
significance of the rescue effect by WT Omi/HtrA2 (Fig. 4D).
Interestingly, the level of mitochondrial ROS could also be
normalized upon re-transfection of Omi/HtrA2 WT as well as
protease-dead (Fig. 4E), suggesting that the morphological
phenotype is not due to increased ROS production. Regulation
of mitochondrial morphology appears to depend on Omi/HtrA2
protease activity, whereas mitochondrial ROS production could
be related to another function of Omi/HtrA2.
It should be noted that the differences observed between
both WT and KO as well as in the vector or WT re-transfectants
were not due to or did not lead to alterations in the
mitochondrial mass as seen by the equal amounts of both the
inner membrane protein ANT and the outer membrane protein
VDAC1 (Fig. 4F). These results indicate that loss of Omi/HtrA2
leads to disturbed mitochondrial function, without changes in
mitochondria mass, and can be rescued by reintroduction of
physiological Omi/HtrA2 protein into the KO background.
Omi/HtrA2 functionally and physically interacts with the
mitochondrial fusion protein OPA1
Our results suggest an involvement of Omi/HtrA2 in the
regulation of mitochondrial morphology. The latter is controlled
by mediators of mitochondrial fission, such as Drp1 and Fis1, and
by mediators of mitochondrial fusion, such as OPA1 andFig. 2 – Effects of Omi/HtrA2 on mitochondrial morphology in M
were concomitantly stained with MitoTracker GreenFM and Hoec
Mitochondrial morphology was classified into 3 categories: elong
the percentage of WT (dark bars) and KO (light bars) cells with
observer blinded to the MEF cell genotype (⁎p< 0.05). Error bars
mitochondria in MEF KO cells (G–I) differed from control MEF W
Examples of mitochondria with a local loss of cristae structures (a
structures (asterisk in H and arrow in G).mitofusins [14]. Interestingly, we discovered a selective increase
of OPA1 protein levels, but not in another mitochondrial fusion
protein (Mfn2) in Triton X-100 extracts prepared from Omi/
HtrA2 KO MEF, when compared to controls (Fig. 5A). Densito-
metric quantification of the effect indicates a significant increase
in mild detergent extractable OPA1 levels in KO cells (Fig. 5B),
without affecting the relative amounts of each isoform. Consis-
tently, we found that re-transfection of KO cells with WT Omi/
HtrA2 not only rescued the observed mitochondrial phenotype
(Figs. 4A, D), but also reverted the increased OPA1 levels to that
seen in WT controls (Figs. 5A, B). This effect was confirmed in
HeLa cells treated with Omi/HtrA2 siRNA. These cells also
displayed elevated mild detergent-extractable OPA1 levels
compared to control siRNA treated cells (Fig. 5C). Importantly,
similar to the elongated mitochondrial phenotype, the altered
OPA1 protein levels could not be rescued by re-transfection of
the protease dead variant of Omi/HtrA2 into the Omi/HtrA2 KO
MEF cells (Fig. 5D).
Since these findings were indicative of a functional relation
between Omi/HtrA2 and OPA1, we investigated a physical
interaction between these two proteins. We observed a direct
interaction of overexpressed FLAG-tagged Omi/HtrA2 protein
with endogenous OPA1 protein in co-immunoprecipitation experi-
ments using HEK293 cells (Fig. 6A). Moreover, endogenous Omi/
HtrA2 was also found to co-immunoprecipitate with OPA1 in
lysates from mouse brain (Fig. 6B). Although some OPA1
unspecifically binds to the agarose (and consequently pullsEF cells. (A, B) Live Omi/HtrA2 WT (A) and KO (B) MEF cells
hst 33342 for 10 min. Size bar corresponds to 10 μm. (C)
ated, middle sized and fragmented. The results are shown as
mitochondria falling into these categories as scored by an
show the SD. (D–I) Electron microscopy shows that
T cells (D–F) by failure to form elaborated cristae structures.
rrow in H and I) or a complete loss of folded inner membrane
Fig. 3 –Mitochondrial morphology in Omi/HtrA2 silenced HeLa and S2R+ cells. (A) Treatment of HeLa cells with Omi/HtrA2 siRNA
greatly reduced the levels of Omi/HtrA2 protein compared to non-transfected (−) and control siRNA treated cells (ctrl). Re-probing
the Western blot for β-actin confirmed equal loading. (B–D) The mitochondrial morphology was investigated in HeLa cells
transfectedwith control siRNA (B) or Omi/HtrA2 siRNA (C). Themitochondria were scored in each cell as either elongated or normal
and quantified (D). Error bars show the SD; ⁎p< 0.005. Scale bar corresponds to 10 μm. (E) Quantitative real-time PCRmeasurement
of Omi/HtrA2 knock down in S2R+ cells compared to control. (F)Western blot of Omi/HtrA2 levels in S2R+ control and Omi/HtrA2
dsRNA treated cells. β-Tubulin was used as a loading control. (G–I) S2R+ cells treated with control (ctrl) (G) or Omi/HtrA2 (H)
dsRNAs stained with mitochondrial dye rhodamine123 dye. Scale bars correspond to 5 μm. (I) Mitochondrial length was quantified
and compared to knock down of known fission and fusion factors (Mfn/Marf, OPA1, Drp1, Fis1) (⁎⁎p<0.01, ⁎⁎⁎p<0.001). Error bars
show the standard error of the mean (SEM).
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HtrA2 in the OPA1 immunoprecipitates compared to the control
without OPA1 antibody.
Omi/HtrA2 affects a Triton X-100 extractable and
proteinase K labile pool of OPA1
The effects of Omi/HtrA2 on OPA1 protein levels appeared to occur
at the post-translational (protein) level. We found no difference in
the mRNA levels of OPA1 between Omi/HtrA2 KO MEF and wild-type controls, as determined by semiquantitative RT-PCR of all
isoforms of OPA1 (Fig. 7A).
Interestingly, loss of Omi/HtrA2 influenced preferentially a
Triton X-100 soluble pool of OPA1. Under harsher detergent
conditions, such as using SDS no difference between Omi/HtrA2
KO MEF cells and WT controls was observed (Fig. 7B, and results
not shown). These findings suggest that Omi/HtrA2 influences
the extractibility of OPA1 that may be related to the submito-
chondrial localization. We therefore performed limited proteol-
ysis experiments on isolated mitochondria. This can be used to
Fig. 4 – Re-transfection of KO MEFs with human WT Omi/HtrA2 rescues the phenotype. (A–D) The mitochondrial morphology of
Omi/HtrA2 KO MEF cells stably overexpressing either human WT Omi/HtrA2 (A), empty vector (B) or a synthetic protease dead
mutant of Omi/HtrA2 (C) was investigated using the same procedure as in Fig. 2. Scale bar corresponds to 10 μm. In the
quantification (D), error bars indicate the SEM (⁎p< 0.05). (E) Stably re-transfected MEF cells were stained with the fluorescent dye
MitoSOX to investigate the levels of intramitochondrial ROS. The procedure was the same as was used for the WT and KO cells. The
result is the mean of three independent experiments and a relative comparison of Omi/HtrA2 KO re-transfected with vector
compared to those re-transfectedwithWTor S306AOmi/HtrA2, whereWTwas set to 1 (⁎p< 0.06). Error bars indicate the SD. (F)WT
and KO MEF cells as well as KO MEFs retransfected with either WT Omi/HtrA2 or empty vector were lysed with 1% Triton X-100 in
TNE. The stable overexpression of human Omi/HtrA2 leads to expression of an ≈50 kDa precursor (arrow head) that is efficiently
processed to the ≈35 kDa mature form (arrow) co-migrating with the endogenous Omi/HtrA2, which is completely absent in KO
MEF cells and vector controls when analyzed by Western blot. To investigate whether there is a change in the mitochondrial
membrane mass, the relative amounts of the outer membrane protein VDAC1 and inner membrane protein ANT were also probed.
β-Actin was used as a loading control.
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mitochondria as the proteinase K digestion consecutively digests
mitochondrial proteins starting from the outer membrane.
Mitochondrial fractions were derived from Omi/HtrA2 KO and
control MEF cells and the relative purity of the subcellular
fractions was verified by probing for VDAC1 and Hsp90,
respectively (Fig. 7C). Interestingly, the accumulated longer
OPA1 isoforms in the Omi/HtrA2 KO cells were degraded more
rapidly (Fig. 7D). Further densitometric analysis of the higher
molecular weight OPA1 band (marked with an arrow head in
Fig. 7D) and the fold change compared to the untreated controls(time point 0; Fig. 7D), clearly indicates that the higher
molecular weight band of OPA1 is more rapidly degraded.
Finally, we noted an increase of the small cytosolic pool of OPA1
in the Omi/HtrA2 KO MEF cells in longer exposures (Fig. 7C).
Release of OPA1 has been described upon disruption of OPA1
engagement in cristae junctions [27,28]. We propose that Omi/
HtrA2 is involved in OPA1 cristae junction complex maintenance,
as Omi/HtrA2 deficient cells show altered mitochondrial ultra-
structure andmore soluble OPA1withinmitochondria and cytosol.
Some of the PK-labile OPA1 could be engaged in mitochondrial
fusion, accounting for the observed mitochondrial elongation in
Fig. 5 – Effects of Omi/HtrA2 on OPA1 protein levels inmouse and human cell lines. (A, B) Omi/HtrA2WT and KOMEF cells, as well as
with WT Omi/HtrA2 and vector stably re-transfected KO cells, were lysed with 1% Triton X-100 in buffer and subjected to
immunoblotting. (A) Western blots were probed for the mitochondrial fusion protein OPA1 and Mfn2. β-Actin was used as a loading
control. (B) Densitometric analysis of OPA1 band intensities, after 1%TritonX-100 in TNE extraction, in three independent experiments
is depicted here (n.s.=not significant, ⁎p< 0.05, ⁎⁎p< 0.01). Error bars indicate the SD. (C) Effects of Omi/HtrA2 on OPA1 levels
were reproduced in HeLa cells. The silencing efficiency as well as the corresponding changes in OPA1 levels was detected in untreated,
control or Omi/HtrA2 silenced HeLa cells lysed with 1% Triton X-100 in buffer and subjected toWestern blot analysis using antibodies
against OPA1, Omi/HtrA2 and β-actin as a loading control. (D) Omi/HtrA2 KO andWTMEF cells were stably re-transfected with either
control vector, WT or protease mutant [S306A]Omi/HtrA2, and the cells were lysed with 1% Triton X-100 buffer and subjected to
Western blot analysis using antibodies against OPA1 , Omi/HtrA2 and β-actin as a loading control.
Fig. 6 – Omi/HtrA2 physically interacts with OPA1. (A) HEK293
cells were stably transfected with FLAG-tagged Omi/HtrA2 (+)
while untransfected cells (−) were used as controls. Lysates
were subjected to Western blot analysis directly (inputs) or
after incubation overnight with anti-FLAG coupled agarose.
Immunoblotswere probedwith anti-OPA1 and anti-Omi/HtrA2
as indicated. The asterisk marks the recombinant form of Omi/
HtrA2. The input sample was taken before adding the agarose.
(B) Co-immunoprecipitation of endogenous Omi/HtrA2 and
OPA1 in lysates from C57/Bl6 mouse brain. Lysates were
subjected to Western blot analysis directly (inputs) or after
incubationovernightwith either proteinG agarose alone (−) or
with anti-OPA1 bound to protein G agarose (+). Immunoblots
were probed with anti-OPA1 and anti-Omi/HtrA2 as indicated.
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into the cytosol may promote a pre-apoptotic state in Omi/HtrA2
KO MEF cells, consistent with the presence of some activated
caspase-3 under basal conditions (data not shown).Discussion
Loss of Omi/HtrA2 function has been linked to neurodegeneration
in two different neurological disorders, namely Huntington's and
Parkinson's disease. Mutations in the Omi/HtrA2 gene that
reduced the serine protease activity in vitro were found in PD
patients and genetic variants that may modulate the expression
levels or the stability of Omi/HtrA2 were described in some PD
populations [9,10]. Although the role of some of these genetic
variants in Omi/HtrA2 is still debated [29,30], a potential
contribution of Omi/HtrA2 to PD pathogenesis is underscored by
its presence in characteristic intraneuronal protein aggregates in
PD that not only contain α-synuclein protein but also show a
specific co-staining with Omi/HtrA2 not observed in other
neurodegenerative disorders [9,31].
Here we present evidence that Omi/HtrA2 is a critical factor for
the maintenance of mitochondrial integrity and that loss of Omi/
HtrA2 function leads to dysfunctional mitochondria. Indeed, we
found that Omi/HtrA2 KO MEFs display an elongated mitochon-
drial phenotype and impaired mitochondrial function as indicated
by increased ROS levels and reduced mitochondrial membrane
potential. Interestingly, the increased ROS levels, unlike the
Fig. 7 – Differences in OPA1 levels are due to protein accessibility. (A) Semiquantitative RT-PCR was performed on mRNA isolated
from Omi/HtrA2 WT or KO and re-transfected MEF cells. There are no differences in the OPA1 mRNA levels (upper panel).
Amplification of β-actin served as loading control (lower panel). (B) For analysis of the full cell content, 150,000 control and Omi/
HtrA2 KOMEF cells were harvested, lysed directly in Laemmli SDS-PAGE sample buffer and analyzed byWestern blot. Immunoblots
were probed with anti-OPA1 (short and long exposure) and anti-Omi/HtrA2 and β-actin was used as a loading control. (C)
Mitochondrial and cytosolic fractions prepared from Omi/HtrA2 WT and KO cells were subjected to Western blotting and analyzed
for localization of both OPA1 and Omi/HtrA2. The purity of the cytosolic (Cyto) andmitochondrial (Mito) fractions was assessed by
probing for Hsp90 and VDAC1, respectively. (D) Mitochondria isolated from control (left lanes) or Omi/HtrA2 KO (right lanes) MEF
cells were subjected to proteinase K digestion for indicated time points. Western blots were prepared and probed with anti-OPA1
and anti-Omi/HtrA2 as indicated. The outer membrane associated protein Fis1 was rapidly degraded whereas the inner membrane
protein prohibitin was shielded. The higher molecular weight OPA1 band densitometrically analyzed (arrow head) is indicated and
the fold change compared to untreated (time point 0) is shown below the Western blot (D).
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suggesting that these are two separate events but both dependent
on the presence of Omi/HtrA2. This also suggests that the
increased ROS levels are not the cause of the elongated
mitochondria seen in cells devoid of Omi/HtrA2.
Our present data indicate that loss of Omi/HtrA2 function
leads to changes in mitochondrial morphology by modulation of
the interacting fusion protein OPA1. Thereby our study provides
first mechanistic insight into the physiological role of Omi/HtrA2
in the regulation of mitochondrial dynamics and maintenance of
mitochondrial homeostasis and supports the pathogenic rele-
vance of loss of Omi/HtrA2 function in neurodegeneration. The
observed interaction of Omi/HtrA2 with OPA1 extends this link
to the molecular level and reveals a novel role of Omi/HtrA2 in
balancing mitochondrial fusion-fission dynamics. Importantly,
the role of Omi/HtrA2 in the regulation of mitochondrial
morphology and the effects of the loss of the protein are not
transient as we observe the same mitochondrial phenotype in
both a model of genetic ablation of Omi/HtrA2, as well as upon
transient knock down of the protein. This contrasts with the
situation where PINK1 is deleted, where the paradigm appliedfor analysis, acute versus chronic, seems crucial for observing
changes in mitochondrial morphology [36]. Furthermore, we
showed that the role of Omi/HtrA2 as a modulator of
mitochondrial morphology is highly conserved as these effects
are independent of cell type and species. In addition, we could
clearly show that this is dependent on the serine protease
activity of Omi/HtrA2. Recently altered mitochondrial dynamics
were linked to neurodegeneration in PD by the functional
characterization of proteins mutated in familial forms of PD
(PINK1 and Parkin). Loss of PINK1 or Parkin function was related
to dysregulation of the mitochondrial fusion-fission machinery
with PINK1 acting upstream of Parkin [21,32]. Omi/HtrA2 has
also been found to be regulated by PINK1 [25], and recent
genetic studies in Drosophila suggest that Omi/HtrA2 acts
downstream of PINK1 but parallel to Parkin in maintaining
mitochondrial integrity in Drosophila [33,34]. It was shown that
the loss of Omi/HtrA2 leads to a weak mitochondrial phenotype
in Drosophila, with only mild alterations in mitochondrial
integrity upon aging that correlated with progressive motor
deficits in these animals [34], which was not described in an
independent model [35]. Here we have studied the effects on
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and found a similarmitochondrial elongation as inmammalian cells.
In our study, loss of Omi/HtrA2 function was not only related to
elongatedmitochondrial morphology seen by light microscopy (Fig.
2), but also with differential extractability of the interacting protein
OPA1. Remarkably, Omi/HtrA2 appears to influence preferentially a
Triton-soluble, proteinase K labile pool of OPA1 protein (Figs. 5 and
7). Furthermore, as OPA1 is known to play a role in maintenance of
the inner membrane structure [27,37], and we see a loss of cristae
and cristae junction structures in the KOMEFs (Fig. 2), it is tempting
to speculate that the easier extractablematerial observed represents
OPA1 not engaged in the tight complex that seals mitochondrial
cristae junctions. Disruption of cristae junctions leads to some
cytosolic release of OPA1 [27,28], and indeed we observe an
elevation of a small cytosolic pool of OPA1 specifically in Omi/
HtrA2 KO MEF cells. We therefore speculate that Omi/HtrA2 might
influence the mitochondrial inner membrane structures and fusion
bymodulating the localization of OPA1 to either the cristae junctions
or the potentiallymore easily extractable fusion complex. Thismight
bemediated by the physical interaction of Omi/HtrA2with OPA1, as
indicated by co-immunoprecipitation experiments.
In summary, we identified for the first time a direct interaction
of Omi/HtrA2 with OPA1, a regulatory component of the
mitochondrial fusion machinery, and demonstrate consequences
of loss of Omi/HtrA2 function on mitochondrial dynamics and
integrity that are relevant for different neurodegenerative dis-
orders like Parkinson's and Huntington's disease.Acknowledgments
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